Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$72.07 USD

72.07
2,377,116

-1.60 (-2.17%)

Updated Aug 27, 2024 03:53 PM ET

After-Market: $72.22 +0.15 (0.21%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Will Core MedSurg Segment Aid Stryker's (SYK) Q4 Earnings?

Stryker's (SYK) Q4 results are likely to be aided by its core MedSurg segment.

Here's Why Momentum Investors Will Love DexCom (DXCM)

Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?

Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.

Varian Medical (VAR) to Report Q1 Earnings: What's in Store?

Strong overseas presence and product launches are likely to aid Varian Medical's (VAR) fiscal first-quarter results.

Sreyoshi Mukherjee headshot

3 Medical Services Stocks to Buy in 2019: HQY, AMEH & OPGN

Here we discuss three profitable Medical Services stocks as the industry booms.

AngioDynamics (ANGO) Q2 Earnings Beat on Gains From NanoKnife

AngioDynamics (ANGO) sees a solid fiscal second quarter; gains from strong segmental contributions.

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.

Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

DexCom Sees Hammer Chart Pattern: Time to Buy?

DexCom has been struggling lately, but the selling pressure may be coming to an end soon.

Sapna Bagaria headshot

4 Healthcare Stocks That Popped More Than 100% in 2018

Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.

Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look

DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.

Sweta Jaiswal headshot

4 Medical Device Stocks That More Than Doubled in 2018

Here are four medical device stocks which have performed really well in 2018 and should be on investors' radar next year as well.

Sreyoshi Mukherjee headshot

5 Stocks That Popped More Than 100% in 2018 Defying All Odds

Five solid picks that defied the problems confronting the U.S. economy.

Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

What Falling Estimates & Price Mean for Alphatec Holdings (ATEC)

Alphatec Holdings (ATEC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

DexCom (DXCM) Down 11.6% Since Last Earnings Report: Can It Rebound?

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Swarup Gupta headshot

5 Stocks to Gain as Fed Chair "Blinks" on Rates

Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks.

Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel

Zacks.com highlights: DexCom, E*TRADE Financial, MCBC Holdings and Quidel

4 Profitable Stocks Boasting Amazingly High Net Income Ratio

Profitability analysis is considered one of the best possible ways to assess the prospects of a company.

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

DexCom's (DXCM) focus on international markets is likely to lend it a competitive edge in the global MedTech space.

DexCom Amends Deal With Verily to Launch Advanced CGM by 2020

DexCom (DXCM) and Verily to collaborate on the development of additional products and software based on DexCom's profile in the future.

Alphabet Halts Glucose Lens Work to Focus on Other Projects

Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.

Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.

DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View

Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.